Healthtech Solutions (OTC: HLTT), focused on acquiring and investing in strategic cutting-edge health care technological opportunities, is among biotech players that have pivoted to a new model wherein multiple portfolio companies operate under one parent organization. Healthtech’s latest acquisition, Varian Biopharmaceuticals, brings to three the number of subsidiaries under its umbrella. “The acquisition of Varian by Healthtech plays to the strengths of the new portfolio model not only in drug pipeline but also by bringing in experts in an area that could attract additional investment,” reads a recent article. A precision oncology company, Varian specializes in developing atypical protein kinase C iota (“aPKCi”) inhibitors for different tumor types. Its two lead candidates are being prepared for clinical trials. The article quotes Healthtech CEO and Chairman David Rubin as saying, “The fact that [Varian Bio is] developing therapies to target difficult-to-treat cancers such as pancreatic cancer demonstrates just how innovative their team is.”
To view the full article, visit https://ibn.fm/Wi77m
About Healthtech Solutions Inc.
Healthtech Solutions is a reporting public company. The board of directors is focusing the company’s resources into creating a platform to acquire and/or invest in cutting-edge health care technology in the medical device biopharma and pharmaceutical fields. The goal is to bring these solutions to market.
To date, Healthtech Solutions has invested in three areas of medical technology breakthrough:
- MediScan Inc., which is developing a technology that converts 2D images from a portable ultrasound machine into digital 3D images to provide better diagnosis and more accurate internal trauma views. The goal is a commercial system that can provide the data equivalent to an X-ray, MRI or CT scan, without radiation and at a lower cost.
- RevHeart Inc., which is advancing critical research into the treatment of COVID-related heart muscle injury.
- Varian Biopharmaceuticals Inc., a precision oncology company, is the first acquisition of Healthtech Oncology Inc.
Healthtech Solutions has a pipeline of additional acquisitions currently under due diligence.
NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://ibn.fm/HLTT
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.